

## Thursday, October 25, 2018

### 2:00 – 2:15pm LB1: Results from the phase 2 NAVIGATE-AD clinical trial evaluating LY3202626 BACE inhibitor in patients with mild Alzheimer's disease dementia

Albert C Lo<sup>1</sup>, Cynthia Duggan Evans<sup>1</sup>, Michele Mancini<sup>1</sup>, Qun Lin, Hong Wang<sup>1</sup>, Peng Liu<sup>1</sup>, Sergey Shcherbinin<sup>1</sup>, Ming Lu<sup>2</sup>, Arnaud Charil<sup>1</sup>, Brian A Willis<sup>1</sup>, Michael Irizarry<sup>3</sup>

<sup>1</sup>Eli Lilly and Company, Indianapolis, IN, USA <sup>2</sup>Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, USA <sup>3</sup>Eli Lilly and Company, Indianapolis IN, USA; now at Eisai Inc, Woodcliff Lake, NJ

### 2:15 – 2:30pm LB 2: Predictors of [<sup>18</sup>F]flortaucipir (tau) load in Alzheimer's disease and other neurodegenerative disorders

Oskar Hansson, MD, PhD<sup>1,2</sup>; Gil D. Rabinovici MD, PhD<sup>3</sup>; Chul H. Lyoo, MD, PhD<sup>4</sup> & Rik Ossenkoppele, PhD<sup>1,5</sup>

<sup>1</sup>Lund University, Clinical Memory Research Unit, Lund, Sweden, <sup>2</sup>Memory Clinic, Skåne University Hospital, Malmö, Sweden, <sup>3</sup>Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center, <sup>4</sup>Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, <sup>5</sup>VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands.

## Friday, October 26, 2018

### 11:00 – 11:30 am LB3: <sup>18</sup>F-AV-1451-A16: A clinico-pathological study of the correspondence between flortaucipir PET imaging and post-mortem assessment of tau pathology

Mark A. Mintun<sup>1,2</sup>, Adam S. Fleisher<sup>2</sup>, Michael D. Devous<sup>2</sup>, Ming Lu<sup>2</sup>, Anupa K. Arora<sup>2</sup>, Thomas G. Beach<sup>3</sup>, Thomas J. Montine<sup>4</sup>, Michael J. Pontecorvo<sup>2</sup>

<sup>1</sup>Eli Lilly and Company, Indianapolis, IN, USA <sup>2</sup>Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA <sup>3</sup>Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA <sup>4</sup>Department of Pathology, Stanford University, Stanford, CA, USA

### 2:45 – 3:00pm LB4: TOMMORROW: a trial to delay the onset of MCI due to AD and qualify a genetic biomarker algorithm: topline results

Robert Alexander, MD<sup>1</sup>, Daniel K. Burns, PhD<sup>2</sup>, Kathleen A. Welsh-Bohmer, PhD<sup>3</sup>, Carl Chiang, PhD<sup>2</sup>, Meredith Culp, BS<sup>4</sup>, Janet O'Neil, MBA<sup>4</sup>, Brenda L. Plassman, PhD<sup>3</sup>, Craig Metz, PhD<sup>2</sup>, Deborah Yarbrough, MS, MBA<sup>4</sup>, Jingtao Wu, PhD<sup>1</sup>, Rebecca Evans, MD<sup>1</sup>, Kumar Budur, MD<sup>4</sup>, Stephen K. Brannan, MD<sup>4</sup>, Ann M. Saunders, PhD<sup>2</sup>, Emiliangelo Ratti, PhD<sup>1</sup>; for the TOMMORROW Study Investigators

<sup>1</sup>Takeda Development Center Americas, Inc., Cambridge, MA – USA <sup>2</sup>Zinfandel Pharmaceuticals, Inc., Durham, NC – USA <sup>3</sup>Duke University Bryan ADRC, Durham, NC – USA <sup>4</sup>Takeda Development Center Americas, Inc., Deerfield, IL – USA

### 3:00 – 3:15pm LB5: Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in participants with mild Alzheimer's disease

Marwan Sabbagh, MD<sup>1</sup>, Imogene Dunn, PhD<sup>2</sup>, Ann Gooch, PhD<sup>2</sup>, Tom Soeder, MS<sup>3</sup>, Karl Kiebertz, MD, MPH<sup>4</sup>, Carmen Valcarce, PhD<sup>2</sup>, Larry D Altstiel, MD, PhD<sup>2\*</sup>, Aaron H Burstein, PharmD<sup>2</sup>

<sup>1</sup>Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA <sup>2</sup>vTv Therapeutics LLC, High Point, NC, USA <sup>3</sup>Cato Research LTD, Durham, NC, USA <sup>4</sup>Clintrex LLC, Longboat Key, FL, USA

**3:15 – 3:30pm LB6: Aducanumab titration dosing regimen: 36-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer’s disease**

Samantha Budd Haeberlein, PhD<sup>1</sup>, Carmen Castrillo-Viguera, MD<sup>1</sup>, Tianle Chen, PhD<sup>1</sup>, John O’Gorman, PhD<sup>1</sup>, Raj Rajagovindan, PhD<sup>1</sup>, Dakshaben Patel, PhD<sup>2</sup> Philipp von Rosenstiel, MD<sup>1</sup>, Guanfang Wang, PhD<sup>3</sup>, Spyros Chalkias, MD<sup>1</sup>, LeAnne Skordos PharmD<sup>1</sup>, Claudia Prada, MD<sup>1</sup>, Christoph Hock, MD<sup>4</sup>, Roger M Nitsch, MD<sup>4</sup>, Alfred Sandrock, MD, PhD<sup>1</sup>

<sup>1</sup>Biogen, Cambridge, MA, USA <sup>2</sup>Biogen, Maidenhead, UK <sup>3</sup>Cytel, Cambridge, MA, USA <sup>4</sup>Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

**3:30 – 3:45pm LB7: Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers**

Harald Hampel, MD, PhD<sup>1</sup>, Mohammad Afshar, MD, PhD<sup>2</sup>, Frédéric Parmentier, PhD<sup>2</sup>, Coralie Williams, MSc<sup>2</sup>, Adrien Etcheto, MSc<sup>2</sup>, Federico Goodsaid, PhD<sup>3</sup>, Christopher U Missling, PhD<sup>4</sup>;

<sup>1</sup>Department of Neurology, Sorbonne University, Paris, France, <sup>2</sup>Ariana Pharma, Paris, France, <sup>3</sup>Regulatory Pathfinders LLC, San Francisco, CA, <sup>4</sup>Anavex Life Sciences Corp., New York, NY

**3:45 – 4:00 pm LB8: Predictive performance of CSF and imaging AD biomarkers in ADNI1/GO/2 MCI participants using the NIA-AA research framework.**

Leslie M Shaw, PhD<sup>1</sup>, Michal Figurski, PhD<sup>1</sup>, Susan Landau, PhD<sup>2</sup>, William Jagust, MD<sup>2</sup>, Clifford R Jack, MD<sup>3</sup>, Paul S Aisen, MD<sup>4</sup>, Ronald C Petersen, MD<sup>3</sup>, Michael W Weiner, MD<sup>5</sup>, John Q Trojanowski, MD, PhD<sup>1</sup>

<sup>1</sup>University of Pennsylvania, Philadelphia – USA <sup>2</sup>University of California, Berkeley, Berkeley – USA <sup>3</sup>Mayo Clinic, Rochester – USA <sup>4</sup>University of Southern California, San Diego – USA <sup>5</sup>University of California, San Francisco – San Francisco – USA